Devimistat (CPI-613) produces the selective toxicity against several tumor cell lines including H460 human lung cancer cells and Saos-2 human sarcoma cells with EC50 of 120 μM and 120 μM, respectively. CPI-613 (240 μM) also induces both apoptotic and non-apoptotic cell death in H460 human lung cancer and Saos-2 human sarcoma cells. Similarly, CPI-613 (10 mg/kg) also produces significant tumor growth inhibition of H460 human non-small cell lung carcinoma in mouse model.
 |
Source | Stem Cells Dev (2017). Figure 8. CPI-613 |
| Method | Amplex Ultra Red (AUR) assay | |
| Cell Lines | KGDHC and PDHC | |
| Concentrations | 10 μM | |
| Incubation Time | 15 min | |
| Results | At lower concentrations, KMV was not as effective as CPI-613 at suppressing ROS formed by pyruvate metabolism. This is in contrast to mitochondria oxidizing α- ketoglutarate where KMV and CPI-613 elicited similar effects. |
 |
Source | Stem Cells Dev (2017). Figure 5. CPI-613 |
| Method | Amplex Ultra Red (AUR) assay | |
| Cell Lines | KGDHC and PDHC | |
| Concentrations | 150 μM | |
| Incubation Time | 15 min | |
| Results | It had been previously shown that 150 μM CPI-613 is effective at inhibiting PDHC and KGDHC. It is important to emphasize that albumin needs to be excluded from reaction mixtures since it can interfere with the CPI-613 mediated inhibition of PDHC or KGDHC. |
| Cell Experiment | |
|---|---|
| Cell lines | BxPC-3 human pancreatic tumor cells |
| Preparation method | BxPC-3 human pancreatic tumor cells were treated with 50 µM CPI-613 or sham treated (i.e., vehicle), whereas the non-transformed NIH-3T3 mouse fibroblast cells were treated with 100 µM CPI-613 or sham treatment (i.e., vehicle), for 6 hours. The duration of treatment with CPI-613 was based on a time course experiment which measured the time taken to induce death in 10-15% of the cells. At the end of the 6-hour treatment period, live cells were selected based on Trypan blue exclusion and quantified using a hemocytometer. |
| Concentrations | 100 µM |
| Incubation time | 6 h |
| Animal Experiment | |
|---|---|
| Animal models | CD1-Nu/Nu female mice |
| Formulation | PBS |
| Dosages | 25 mg/kg |
| Administration | i.p. |
| Molecular Weight | 388.59 |
| Formula | C22H28O2S2 |
| CAS Number | 95809-78-2 |
| Solubility (25°C) | DMSO 48 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Dehydrogenase Products |
|---|
| MTHFD2-IN-4
MTHFD2-IN-4, tricyclic coumarin derivative, is a potent MTHFD2 inhibitor. |
| MTHFD2-IN-4 sodium
MTHFD2-IN-4 sodium, tricyclic coumarin derivative, is a potent MTHFD2 inhibitor. |
| MTHFD2-IN-3
MTHFD2-IN-3 is a potent methylenetetrahydrofolate dehydrogenase (MTHFD2) inhibitor. |
| MTHFD2-IN-2
MTHFD2-IN-2 is a potent methylenetetrahydrofolate dehydrogenase (MTHFD2) inhibitor. |
| MTHFD2-IN-1
MTHFD2-IN-1 is a potent methylenetetrahydrofolate dehydrogenase (MTHFD2) inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
